MARKET

NTLA

NTLA

Intellia Therape
NASDAQ
55.83
-0.13
-0.23%
Pre Market: 57.99 +2.16 +3.87% 08:20 10/04 EDT
OPEN
57.06
PREV CLOSE
55.96
HIGH
57.43
LOW
54.43
VOLUME
191
TURNOVER
--
52 WEEK HIGH
143.92
52 WEEK LOW
37.08
MARKET CAP
4.24B
P/E (TTM)
-10.4232
1D
5D
1M
3M
1Y
5Y
Intellia Therapeutics to Present at October Healthcare Investor Conferences
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced th...
GlobeNewswire · 09/26 11:30
The Top 5 Stocks Cathie Wood Is Buying This Week
Investor Place · 09/23 20:43
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022
Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago quarter.
Benzinga · 09/21 14:04
JP Morgan Initiates Coverage On Intellia Therapeutics with Overweight Rating, Announces Price Target of $85
JP Morgan analyst Brian Cheng initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Overweight rating and announces Price Target of $85.
Benzinga · 09/21 11:45
JPMorgan Starts Intellia Therapeutics at Overweight With $85 Price Target
JPMorgan Starts Intellia Therapeutics at Overweight With $85 Price Target
MT Newswires · 09/21 06:51
5 Top Stocks Cathie Wood Is Buying Right Now
Investor Place · 09/19 20:30
Cathie Wood is Buying These 10 Stocks in September
In this article, we discuss 10 stocks that Cathie Wood is buying in September. If you want to see more stocks that Wood purchased this month, check out Cathie Wood is Buying These 5 Stocks in September. The mass selloff in the stock market after August’s b...
Insider Monkey · 09/19 20:26
SVB Leerink Maintains Outperform Rating for Intellia Therapeutics: Here's What You Need To Know
SVB Leerink has decided to maintain its Outperform rating of Intellia Therapeutics (NASDAQ:NTLA) and raise its price target from $152.00 to $158.00. Shares of Intellia Therapeutics are trading down 5.55% over the last 24 hours, at $62.06 per share.
Benzinga · 09/19 16:06
More
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage genome editing company. The Company is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). The Company is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned T cell receptor (TCR)-T cell candidate, NTLA-5001 for the treatment of acute myeloid leukemia (AML) and hematopoietic stem cells (HSCs) for the treatment of sickle cell disease.

Webull offers kinds of Intellia Therapeutics Inc stock information, including NASDAQ:NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NTLA stock methods without spending real money on the virtual paper trading platform.